Bookmark and Share

$CLXPF Why Companies Should Manufacture Psychedelic Pharmaceuticals on Large Scale

The development of a new class of pharmaceutical medications made from psychedelic fungi and plants has brought medical science closer to making breakthroughs that address the global mental health crisis caused by the pandemic. These drugs have shown massive potential in the treatment of chronic depression.

However, there are challenges that come with the development of standardized organic compounds to help treat more than a billion individuals globally for various mental health conditions.

Frankly speaking, it’s complicated and costly to separate active ingredients in multi-compound organic substances. Globally, this has not been done on a broad scale anywhere, primarily for two main reasons.

The first entails the logistical and technological challenges of producing these mushrooms and plants to be replicated in large numbers for their chemical consistency and potency while the second factor stems from the fact that, until recently, psychedelics had been banned from being researched from the 1970s. The ban was imposed because the substances were considered drugs that did not offer any medical efficacy and would likely be misused.

Despite many years of psychedelics prohibition, societal barriers that would hinder the acceptance of psychedelics as reputable forms of medicine seem to be fading away. This would explain why laws that govern drugs have slackened to permit clinical studies on these substances, with the U.S. Food and Drug Administration (“FDA”) being supportive of research.

It is estimated that currently about 200 biotechnology start-up companies in Europe and North America are looking to get into the multibillion-dollar market for psychedelic therapies and legal psychedelic medications. Most of these companies are experimenting with psilocybin, the active psychedelic ingredient found in magic mushrooms that can be used to treat severe treatment-resistant depression as well as other mental health conditions.

According to the World Economic Forum, the indirect and direct costs of the mental health epidemic in the society total trillions of dollars annually. The Lancet Commission estimates that this figure will increase to $16 trillion in the near future when spending on law and order, education and social welfare as well as loss of productivity is factored in.

This is why the development of high efficacious, nonaddictive and safe psychedelic drugs could not come at a better time. Studies have shown that roughly 2 billion individuals are affected by addictions, disorders and other mental conditions that can be treated using psychedelic compounds. These include individuals who experience PTSD, addictions to cigarettes and alcohol, depression and anxiety.

With enough clinical evidence backing the science behind psychedelics’ healing properties, demand for these psychedelic drugs is bound to surge, signaling that this is an ideal time to manufacture pharmaceutical-grade psychedelic compounds on an industrial scale.

In related news, Cybin Inc. (NEO: CYBN) (OTC: CLXPF) has announced that it has concluded a deal to access the Kernel Flow system, which will be crucial as the therapeutic potential of psychedelic medicines under research is analyzed in real time.

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (OTC: CLXPF) are available in the company’s newsroom at

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Thursday, March 4th, 2021 Uncategorized
Top Small Cap Market News